Richard Spivey Net Worth

Richard Spivey biography

Dr. Richard N. Spivey Ph.D. is Independent Director of the company. Dr. Spivey has over 30 years of experience in research and development at leading global pharmaceutical companies. Dr. Spivey currently serves as a scientific advisor to the pharmaceutical industry. From 2010 to 2015, Dr. Spivey served as senior vice president of global regulatory affairs at Allergan. From 2002 to 2010, Dr. Spivey worked with Meda AB, a pharmaceutical company, after its acquisition of MedPointe Pharmaceuticals, serving as chief scientific officer and head of research and development for both. Earlier in his career, Dr. Spivey worked for pharmaceutical companies Pharmacia Corporation (now part of Pfizer), Schering-Plough Corporation (now part of Merck & Co.), Parke-Davis/Warner-Lambert (now part of Pfizer), and Boots Pharmaceuticals, Inc. Dr. Spivey previously served on the board of directors of Inotek Pharmaceuticals Corporation (now Rocket Pharmaceuticals, Inc.). Dr. Spivey received a Ph.D. in Pharmacy Administration from the University of Minnesota and a Pharm.D. from the University of Southern California. Dr. Spivey has been chosen to serve on our Board due to his extensive and distinguished experience in drug development and regulatory affairs.

What is the salary of Richard Spivey?

As the Independent Director of Adverum Biotechnologies Inc, the total compensation of Richard Spivey at Adverum Biotechnologies Inc is $483,851. There are 9 executives at Adverum Biotechnologies Inc getting paid more, with Leone Patterson having the highest compensation of $2,830,320.

How old is Richard Spivey?

Richard Spivey is 69, he's been the Independent Director of Adverum Biotechnologies Inc since 2017. There are no older and 18 younger executives at Adverum Biotechnologies Inc.

What's Richard Spivey's mailing address?

Richard's mailing address filed with the SEC is C/O ADVERUM BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, MENLO PARK, CA, 94025.

Insiders trading at Adverum Biotechnologies Inc

Over the last 9 years, insiders at Adverum Biotechnologies Inc have traded over $1,591,374 worth of Adverum Biotechnologies Inc stock and bought 912,973 units worth $4,153,055 . The most active insiders traders include Patrick Machado, Braden Michael Leonard és Thomas Woiwode. On average, Adverum Biotechnologies Inc executives and independent directors trade stock every 40 days with the average trade being worth of $200,186. The most recent stock trade was executed by Braden Michael Leonard on 30 July 2024, trading 85,800 units of ADVM stock currently worth $613,470.

What does Adverum Biotechnologies Inc do?

adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.

Adverum Biotechnologies Inc executives and stock owners

Adverum Biotechnologies Inc executives and other stock owners filed with the SEC include:

• Leone Patterson,
  President
• Thomas Leung,
  Chief Financial Officer
• Aaron Osborne,
  Chief Medical Officer
• Dr. Laurent Fischer,
  Pres, CEO, Interim CMO & Director
• Dr. Brigit Riley Ph.D.,
  Chief Scientific Officer
• Rekha Hemrajani,
  Independent Director
• James Scopa,
  Independent Director
• Mark Lupher,
  Independent Director
• Patrick Machado,
  Independent Chairman of the Board
• Richard Spivey,
  Independent Director
• Eric Carter,
  Independent Director
• Thomas Woiwode,
  Independent Director
• Mehdi Gasmi,
  Director
• Myesha Lacy,
  Vice President, Investor Relations and Corporate Communications
• Scott Whitcup,
  Independent Director
• Peter Soparkar,
  Chief legal officer
• Christopher Morrison,
  Vice President - Process Development
• Thomas Kochy,
  Vice President - Commercial and Program Strategy
• Heikki Jouttijarvi,
  Vice President - Manufacturing
• Angela Thedinga,
  Chief Technology Officer
• Laurent Fischer,
  Chief Executive Officer, Director
• Carla Fiankan,
  Sr. VP of Regulatory Affairs
• Nancy E. Pecota,
  Principal Accounting Officer
• John W. Rakow J.D.,
  Sr. VP, Gen. Counsel & Acting CFO
• Anand Reddi,
  VP, Head of Corp. Strategy & External Affairs and Engagement
• Michael Steel,
  Sr. VP of Quality
• Dr. Jim Wang Ph.D.,
  Sr. VP & Head of Regulatory Affairs
• Dena House,
  Sr. VP of HR, Organizational Devel. & Learning
• Kishor Peter Soparkar J.D.,
  Chief Operating Officer
• Dr. Rupert D'Souza M.B.A., Ph.D.,
  Chief Financial Officer
• Steven Daniel Schwartz,
  Director
• Samuel B. Barone,
  SVP, Clinical Development
• Athena Countouriotis,
  SVP, Chief Medical Officer
• Mitchell H. Finer,
  Director
• Carlo Russo,
  EVP and Chief Medical Officer
• Jennifer C. Cheng,
  General Counsel
• Amber Salzman,
  President and CEO
• Paul B Cleveland,
  Chief Executive Officer
• Richard Beckman,
  Chief Medical Officer
• Szilard Kiss,
  
• Soo Hong,
  
• Rabia Gurses Ozden,
  Chief Medical Officer
• Linda M Rubinstein,
  CHIEF FINANCIAL OFFICER
• Dawn Svoronos,
  
• Reed Vaughn Tuckson,
  
• Rupert D'souza,
  Chief Financial Officer
• Julie Clark,
  Chief Medical Officer
• Setareh Seyedkazemi,
  CHIEF DEVELOPMENT OFFICER
• Braden Michael Leonard,
  
• Brigit Riley,
  Chief Scientific Officer
• John Rakow,
  SVP, Genl Counsel, Acting CFO
• C. David Nicholson,,